SAVA Cassava Sciences

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

- Call-in on Tuesday, August 3rd at 9 a.m. ET -

AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the market opens, followed by a conference call.

Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Company’s growth strategy.

The conference call is scheduled to begin at 9:00 am ET on Tuesday, August 3, 2021. Please dial in 15 minutes in advance to ensure a timely connection to the call.

Conference call detail are as follows:

Toll Free:

  1-888-254-3590

Toll/International:

 1-323-794-2575

After the live call, the event will be archived on the ‘Investors’ page of the Company’s website: .

Live Event Click to Join Link (for participant entry):





 
  • Participants can use Guest dial-in #s above and be answered by an operator OR click the Click to Join link for instant telephone access to the event
  • Click to Join link will be made active 15 minutes prior to scheduled start time.

About Alzheimer’s Disease

Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050.1 The annual global cost of dementia is now above $1 trillion, according to Alzheimer’s Disease International, a charitable organization.

About Cassava Sciences, Inc.

Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For more information, please visit: .

For More Information Contact:

Eric Schoen, Chief Financial Officer



(512) 501-2450

For information regarding risks related to our business, investors please consult our filings with the SEC, which are available on the SEC's website at .

1 Alzheimer's Disease International, Dementia Statistics, available on-line.



EN
02/08/2021

Underlying

SAVACassava Sciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cassava Sciences

 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Sim...

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints  The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms simufilam’s favorable safety profile in these studies Exploratory post-hoc analyses offer informative insights AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company...

January 13, 2026 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Announces Agreement to Settle Securities Class Action Litigati...

Cassava Announces Agreement to Settle Securities Class Action Litigation AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it has reached a definitive agreement to resolve the previously disclosed consolidated securities class action litigation pending in the United States District Court for the Western District of Texas Austi...

December 23, 2025 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Reports Q3 2025 Financials Results and Provides Business Updat...

Cassava Reports Q3 2025 Financials Results and Provides Business Update Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigation...

November 12, 2025 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value ...

October 22, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
KMX CARMAX INC.
VIRC Virco Manufactu... ... (+49)

InsiderInsights Weekly Report: October 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

KMX CARMAX INC.
VIRC VIRCO MANUFACTURING CORP.
THFF FIRST FINANCIAL CORP. (INDIANA)
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
FDS FACTSET RESEARCH SYSTEMS INC.
CAPL CROSSAMERICA PARTNERS LP
CALM CAL-MAINE FOODS INC.
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
ASA ASA
ADC AGREE REALTY CORPORATION
RIGN TRANSOCEAN LTD.
RVP RETRACTABLE TECHNOLOGIES INC.
TRT TRIO TECH INTERNATIONAL
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
AMBC AMBAC FINANCIAL GROUP INC.
GWRS GLOBAL WATER RESOURCES
BRT BRT APARTMENTS
ZIVO ZIVO BIOSCIENCE
CPSH INC.
FUND CPS TECHNOLOGIES
FGBI ROYCE FOCUS TRUST
STRO INC.
SAVA FIRST GUARANTY BANCSHARES
DX SUTRO BIOPHARMA
PNTG CASSAVA SCIENCES
PCB DYNEX CAPITAL INC.
WWR PENNANT GROUP
ACET PACIFIC CITY FINANCIAL CORP
ALTM WESTWATER RESOURCES
CGEM ADICET BIO INC
OPEN ALTUS MIDSTREAM COMPANY (A)
GGZ CULLINAN ONCOLOGY INC
IMRX OPENDOOR TECHNOLOGIES INC.
REFI GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
PEPG IMMUNEERING CORP
VANI CHICAGO ATLANTIC REAL ESTATE FINANCE INC
UAMY PEPGEN INC
SOC VIVANI MEDICAL INC
LAW U S ANTIMONY CORP
MRAI SABLE OFFSHORE CORP
HYMC CS DISCO INC
SABS MARPAI
INC.
HYCROFT MINING HOLDING CORPORATION
BIG CYPRESS ACQUISITION CORP.
10/19/25 October 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch